

Hansoh Pharmaceutical Group (3692 HK)



Last price: HK\$31.52

Support levels: HK\$29.16/HK\$28.14

Resistance levels: HK\$34.56/HK\$38.40

Technical View:

The price has been bottoming out and has formed a double bottom chart pattern. Immediate buying urgency is confirmed by a successful penetration of the intermediate pivot neckline, accompanied by the RSI crossing above its 50-neutral baseline. With the primary structural accumulation phase concluded and momentum shifting back to the long side, the technical framework favours a near-term continuous move higher.

Average timeframe: Around two weeks.

Sinotruk Hong Kong (3808 HK)



Last price: HK\$40.26

Support levels: HK\$37.42/HK\$35.54

Resistance levels: HK\$45.24/HK\$48.40

Technical View:

The price has successfully defended its previous low support floor. Near-term buying urgency is expanding at this inflection point, highlighted by the RSI curling upward toward neutral territory. With selling pressure thoroughly neutralised at the previous baseline and momentum parameters actively shifting back to the long side, the technical framework favours a near-term extension higher.

Average timeframe: Around two weeks.

Analyst

Greater China Research Team

research-hk@uobkh.com

Tham Mun Hon, CFA

+852 2236 6799

munhon.tham@uobkh.com

IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS

This report is provided subject to various disclosures and disclaimers (the "Disclosures / Disclaimers") which form an integral part of this report and are available at the following link:
<https://research-api.uobkayhian.com/assets/disclaimer/0e6d602f-adeb-45f8-9dea-5d5591daae87> or by scanning the QR code below:



The Disclosures / Disclaimers contain important information, including without limitation, (a) exclusions of liability, (b) confidentiality obligations, (c) restrictions on publication, circulation, reproduction, distribution and use of the report, (d) potential conflicts of interest, and (e) disclosures and requirements specific to recipients in the United States and other applicable jurisdictions.

Specifically, this report is intended for general circulation and informational purposes only and does not take into account the specific investment objectives, financial situation, or particular needs of any individual person. It is not intended to constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment, taking into account your specific objectives, financial situation and needs, before making any investment decision. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report.

Recipients of this report must carefully read, review and understand the full Disclosures / Disclaimers before using or relying on any information in this report. By accessing, receiving or using this report, you acknowledge and confirm that you have read, understood, accepted and agreed to be bound by the Disclosures / Disclaimers (as may be amended or updated from time to time) in full."